# Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

> **NCT05397639** · PHASE3 · RECRUITING · sponsor: **Suven Life Sciences Limited** · enrollment: 375 (estimated)

## Conditions studied

- Agitation
- Alzheimer's Type Dementia

## Interventions

- **DRUG:** Masupirdine 50 mg
- **DRUG:** Masupirdine 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05397639
- **Lead sponsor:** Suven Life Sciences Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 375 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05397639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05397639, "Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT05397639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*